Scarica l'app Stockscreener
18.53
3.46%
0.62
Dopo l'orario di chiusura:
18.51
-0.02
-0.11%
Immunome Inc Borsa (IMNM) Ultime notizie
(IMNM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
How Immunome’s First-in-Human IM-1617 ADC Trial At Immunome (IMNM) Has Changed Its Investment Story - simplywall.st
IMNM (NASDAQ: IMNM) director plans to sell 60,000 shares via option - Stock Titan
Immunome (IMNM) director receives 9,897 stock options at $18.16 strike price - Stock Titan
[Form 4] Immunome Inc. Insider Trading Activity - Stock Titan
Immunome (IMNM) director granted stock options on 9,897 common shares - Stock Titan
Immunome (IMNM) director-linked entity awarded 9,897 stock options at $18.16 strike - Stock Titan
Immunome (IMNM) director Carol Schafer receives grant of 9,897 stock options - Stock Titan
Immunome (IMNM) 2026 meeting: directors elected, pay and auditor votes pass - Stock Titan
IMNM Reiterated by Wedbush -- Price Target Maintained at $31 - GuruFocus
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Immunome (IMNM) Begins First Phase 1 Trial for IM-1617 - GuruFocus
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - BioSpace
Immunome doses first patient in IM-1617 cancer therapy trial - Investing.com
Immunome director Bienaime sells $203k, buys $204k in same-day trades By Investing.com - Investing.com Australia
Immunome director Bienaime sells $203k, buys $204k in same-day trades - Investing.com Australia
IMNM SEC FilingsImmunome Inc 10-K, 10-Q, 8-K Forms - Stock Titan
IMNM: Varegacestat nears launch with strong data; ADC pipeline advances with key readouts ahead - TradingView
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis (NASDAQ:IMNM) - Seeking Alpha
Can Varegacestat’s Broad Efficacy Profile Redefine Immunome’s (IMNM) Rare Oncology Investment Narrative? - simplywall.st
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Immunome earnings up next: Cash burn eyed after NDA filing By Investing.com - Investing.com UK
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA FilingHas The Bull Case Changed? - Yahoo Finance
Immunome earnings up next: Cash burn eyed after NDA filing - Investing.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - standard-journal.com
A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage - Sahm
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33 - Moomoo
H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Barclays Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Va - GuruFocus
Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Varegacestat - GuruFocus
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacesta - The National Law Review
Immunome’s Varegacestat Phase 3 RINGSIDE Trial Results Presented at ASCO 2026 Show Progression-Free Survival Data in Desmoid Tumors - geneonline.com
Immunome announced positive clinical trial results for its drug Varegacestat. - Bitget
Immunome presents phase 3 trial results for desmoid tumor drug By Investing.com - Investing.com South Africa
Immunome presents phase 3 trial results for desmoid tumor drug - Investing.com
Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints - TradingView
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting - Business Wire
Does Barclays’ Bullish Stance Refocus Immunome’s (IMNM) Investment Narrative on Its ADC Platform? - simplywall.st
Immunome (IMNM) Receives a New Rating from Barclays - The Globe and Mail
IMNM Maintained by Truist Securities -- Price Target Raised to $37 - GuruFocus
Immunome Is Maintained at Buy by Truist Securities - Moomoo
Immunome Price Target Raised to $37.00/Share From $36.00 by Truist Securities - Moomoo
IMNM Initiates Coverage On Barclays -- Rating Set to Overweight - GuruFocus
Truist raises Immunome stock price target on desmoid tumor drug By Investing.com - Investing.com Australia
Truist Financial Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $37 - Moomoo
Barclays initiates Immunome stock coverage with overweight rating - Investing.com UK
Truist raises Immunome stock price target on desmoid tumor drug - Investing.com
Barclays Initiates Immunome at Overweight With $36 Price Target - marketscreener.com
Barclays initiates Immunome stock coverage with overweight rating By Investing.com - Investing.com Australia
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):